Genmab raises 2014 profit forecast, expects milestone
May 01, 2014 at 16:00 PM EDT
COPENHAGEN, May 1 (Reuters) - Danish biotech firm Genmab raised its full-year profit forecast after announcing its partner will start a new phase III clinical study of a cancer drug, a move which will give it a milestone payment of 50 million Danish crowns ($9.3 million).